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Background: Glucocorticoid (GC) resistance is a major barrier in COPD treatment. We have shown increased
expression of the drug efflux pump, Pgp1 in cytotoxic/pro-inflammatory lymphocytes in COPD. Loss of lymphocyte
co-stimulatory molecule CD28 (lymphocyte senescence) was associated with a further increase in their
pro-inflammatory/cytotoxic potential and resistance to GC. We hypothesized that lymphocyte senescence
and increased Pgp1 are also associated with down-regulation of the GC receptor (GCR).
Methods: Blood was collected from 10 COPD and 10 healthy aged-matched controls. Flow cytometry was applied to
assess intracellular pro-inflammatory cytokines, CD28, Pgp1, GCR, steroid binding and relative cytoplasm/nuclear GCR
by CD28+ and CD28null T, NKT-like cells. GCR localization was confirmed by fluorescent microscopy.
Results: COPD was associated with increased numbers of CD28nullCD8+ T and NKT-like cells. Loss of CD28 was
associated with an increased percentage of T and NKT-like cells producing IFNγ or TNFα and associated with a
loss of GCR and Dex-Fluor staining but unchanged Pgp1. There was a significant loss of GCR in CD8 + CD28null
compared with CD8 + CD28+ T and NKT-like cells from both COPD and controls (eg, mean ± SEM 8 ± 3% GCR +
CD8 + CD28null T-cells vs 49 ± 5% GCR + CD8 + CD28+ T-cells in COPD). There was a significant negative correlation
between GCR expression and IFNγ and TNFα production by T and NKT-like cells(eg, COPD: T-cell IFNγ R = −.615; ) and
with FEV1 in COPD (R = −.777).
Conclusions: COPD is associated with loss of GCR in senescent CD28null and NKT-like cells suggesting alternative
treatment options to GC are required to inhibit these pro-inflammatory/cytotoxic cells.
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Chronic obstructive pulmonary disease (COPD) is a lead-
ing cause of death world wide. Existing treatments are
largely symptomatic and the use of anti-inflammatory cor-
ticosteroids has no proven disease modifying effect [1].
The mechanisms underlying this resistance, particularly in
lymphocytes, are largely unknown [2] Our group has re-
ported increased production of Th1 pro-inflammatory cy-
tokines IFN-γ and TNF-α by CD8+ T cells in peripheral
blood and lungs [3] and higher levels of the cytotoxic
mediators granzyme b and perforin in peripheral blood* Correspondence: greg.hodge@health.sa.gov.au
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unless otherwise stated.in current and ex-smoker COPD patients compared to
healthy smokers and never-smokers [4].
Our previous studies have focused on identifying the
lymphocyte subset/s resistant to current therapeutics.
We have shown that COPD is associated with increased
CD8/CD28null cells in the peripheral blood of both
current and ex-smoker COPD groups and these cells
expressed more IFNγ, TNFα, granzyme B and perforin
than CD8 + CD28+ cells [5]. CD8/CD28null oligoclonal
T-cells have been reported in autoimmune diseases in-
cluding granulomatous interstitial lung diseases [6] and
in the aging immune system and its relationship to the
development of COPD [7]. CD8/CD28null clones divide
faster and live longer than CD8CD28+ T cells due toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and a different response to regulatory cytokines [8].
Recently we also showed NKT-like and NK cells were
increased in bronchoalveolar lavage (BAL) of COPD pa-
tients and this was associated with increased cytotox-
icity by both cell types [9]. CD8 + CD28null NKT-like
cells have been shown to be more pro-inflammatory and
cytotoxic than CD8 + CD28+ NKT-like cells in lung
transplant patients diagnosed with bronchiolitis obliter-
ans syndrome [10], a further chronic inflammatory
lung disease.
Importantly, the drug efflux pump, Pgp-1 was shown
to be up-regulated in pro-inflammatory steroid resistant
T and NKT-like cells in the peripheral blood of patients
with COPD [11]. While elevated levels of Pgp-1 may
contribute to a relative resistance to corticosteroids, it is
likely that additional factors such as reduced levels of
glucocorticoid receptors (GCR) in these pro-inflammatory
lymphocytes may also play a role.
To investigate this hypothesis, we determined whether
peripheral blood CD28null T cells (particularly CD8+)
and NKT-like cells from COPD patients express reduced
levels of GCR and/or increased Pgp-1 and whether loss
of GCR (and/or increased Pgp-1) is associated with in-
creased pro-inflammatory cytokines.
Methods
Patient and control groups
COPD volunteers were specifically recruited for the
study and informed consent obtained. There was no ex-
acerbation of COPD for 6 weeks prior. Subjects with
other co-existing lung disease or malignancy or aged
greater than 75y were excluded. Ethics approval was ob-
tained from the Royal Adelaide Hospital and the experi-
ments were conducted with the understanding and the
written consent of each participant. COPD was diag-
nosed using the GOLD criteria with clinical correlation
(mild COPD: FEV1/FVC < 70% but FEV1 ≥ 80% pre-
dicted; moderate COPD FEV1 50% ≤ 80% predicted, se-
vere COPD FEV1 30% ≤ 50% predicted, very severe
COPD FEV1 < 30%) [12]. Blood was collected from 10
patients with COPD (Table 1) all of whom were ex-Table 1 Demographic details of the COPD and control
group
Subjects Controls COPD
No. of subjects 10 10
Age (years) 49 (±8) 58 (±16)*
FEV1, % pred 108.4 (±9) 60.1 (±20)
FEV1, % FVC 96 (±12) 58 (±15)*
Male/Female 8/6 6/4
Data showing mean ± SD.
Abbreviations: FEV1 forced expiratory volume in 1 second, FVC forced vital
capacity. *P < 0.05 compared to controls.smokers (at least one year) with an average of 37 pack
years. No patients were receiving oral GCS.
Blood was also obtained from 10 aged-matched non-
smoking volunteers (Table 1) with normal lung function.
These were healthy, recruited volunteers with no history
of airways disease. All subjects underwent spirometry as
part of their routine clinical assessment. Venous blood
was collected into 10 U/mL preservative free sodium
heparin (DBL, Sydney, Australia), and maintained at 4°C
until processing. All patients were submitted to the same
protocol and analysis performed retrospectively.
Leucocyte stimulation
Leucocyte stimulation was required for intracellular cyto-
kine and Pgp1 expression [11,13]. Consistent with previ-
ous reports [14,15] preliminary experiments showed GCR
expression was detected in less than 2% of unstimulated T
cells but GCR expression was significantly upregulated in
T and NKT-like cells following the same stimulation as for
intracellular cytokine and Pgp1 detection. One mL ali-
quots of blood diluted 1:2 with RPMI 1640 medium
(Gibco, New York, USA) supplemented with 125 U/mL
penicillin and 125 U/mL streptomycin) were placed in a
10 mL sterile conical PVC tubes (Johns Professional
Products, Sydney, Australia). Phorbol myristate (25 ng/mL)
(Sigma, Sydney, Australia) and ionomycin (1 μg/mL)
(Sigma) was added. Brefeldin A (10 μg/mL) (Sigma) was
added as a “Golgi block” and the tubes re-incubated in a
humidified 5% CO2/95% air atmosphere at 37°C for
16 h. Preliminary studies showed that addition of Brefeldin
A was shown not to affect Pgp1 or GCR expression in T
and NKT-like cells (not shown).
Pgp1 and GCR expression by CD28+ and CD28null T,
NKT-like cells
Following stimulation as described above, 350 μL aliquots
of cells were treated with 2 mL FACSLyse (BD Bioscience,
Sydney, Australia) for 10 min. Cells were centrifuged,
supernatant discarded and 500 mL FACSPerm (BD) added
for 10 min. Two mL 0 · 5% bovine serum albumin (BSA)
(Sigma) in IsoFlow (Beckman Coulter, Sydney, Australia)
was then added and the tubes centrifuged at 300 g for
5 min. After decanting supernatant, Fc receptors were
blocked with 10 mL human immunoglobulin (Intragam,
CSL, Melbourne, Australia) for 10 min at room temperature.
Five μL of mouse anti-human GCR (clone 5E4, Serotec,
Sydney, Australia; raised against a conserved sequence of
the regulatory part of the receptor- amino acids 150–176)
as previously reported [16] was added to cells for 15 min,
and following washing (as above), 5 μL rat anti-mouse
IgG1 V450 (BD) was added for 15 min. Following wash-
ing, 5 μL of appropriately diluted CD3 perCP.Cy5.5 (BD),
Pgp1 PE (BD), CD28 PECY7 (BD), CD56 APC (Beckman
Coulter), CD8 APCH7 (BD) and CD45 V500 (BD) were
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were washed and events acquired and analyzed as previ-
ously reported [11,13].
Pgp1, GCR, IFNγ and TNFα expression by CD28+ and
CD28null T, NKT-like cells
To determine possible association of pro-inflammatory
cytokines and Pgp1 and GCR expression by CD28+ and
CD28null T and NKT-like cells, whole blood was stimu-
lated as described above. Following stimulation and pro-
cessing, cells were labeled with anti-GCR as described
above, then 5 μL of appropriately diluted IFNγ FITC
(BD), TNFα FITC (BD), Pgp1 PE (BD), CD3 perCP.
Cy5.5 (BD), CD28 PECY7 (BD), CD56 APC (Beckman
Coulter), CD8 APCH7 (BD) and CD45 V500 (BD) were
added for 15 min in the dark at room temperature. Cells
were washed and events acquired and analyzed as de-
scribed [5,11,13].
Correlation of GCR with steroid binding capacity in
CD28+ and CD28null T and NKT-like cells
To correlate steroid binding with GCR expression of
CD28+ and CD28 null T and NKT-like subsets, 350 μL ali-
quots of cells following stimulation as described above were
added to 10−5 M Dexamethasone (Hospira, Melbourne,
Victoria, Australia) for 30 min in a humidified 5% CO2/95%
air atmosphere at 37°C followed by 5 μL Dexamethasone
Fluorescein (Molecular Probes, Life Technologies, Sydney,
Australia) for a further 30 min in a humidified 5% CO2/
95% air atmosphere at 37°C. Cells were then washed,
stained with monoclonal antibodies and analysed as de-
scribed above.
Cytoplasm/nuclear GCR expression by CD28+ and
CD28null T, NKT-like cells
To determine the location of GCR expression in CD28+
and CD28null T and NKT-like cells differential staining
of whole blood following stimulation (as described
above) using reagents to sequentially permeabilise the
cytoplasm and nucleus as previously described [17].
Briefly, following stimulation, 350 μL aliquots of stimulated
whole blood were treated with FACSLyse as described
above and following centrifugation cell cytoplasmic mem-
brane was permeabilised with 0.1% saponin for 10 mins.
Following centrifugation, cells were resuspended in 100 μL
0.1% saponin then labeled with anti-GCR as described
above. Following washing in 0.1% saponin, cells were
stained with rat anti-mouse IgG1 V450 (BD) for 10 min.
After washing in 0.1% saponin, the cells were permeabilised
with 500 μL 0.1% Triton in PBS for 10 min. Cells were then
incubated with anti-GCR as described above, followed by
rat anti-mouse IgG1 PE for 10 min. After washing in 2 mls
0.5% BSA in FACSFlow, cells were stained with 5 μL of ap-
propriately diluted CD3 perCP.Cy5.5 (BD), CD28 PECY7(BD), CD56 APC (Beckman Coulter), CD8 APCH7 (BD)
and CD45 V500 (BD) for 10 min. After washing, data was
acquired as described above.
GCR expression in CD28+ and CD28null T cells by
Fluorescent Microscopy
PBMC were isolated from blood of a cohort of 3 control
and 3 COPD patients by standard density gradient centri-
fugation and cells re-suspended at 1 × 107 mL in RPMI
1640 medium. Following stimulation as described above,
25 μL of appropriately diluted CD3 perCP.CY5.5 (BD),
CD28 PE.CY7 (BD), CD56 APC (Beckman Coulter), CD8
APC.CY7 (BD) and CD45 V500 (BD) monoclonal antibodies
were added for 15 min in the dark at room temperature.
Cells were washed and resuspended in 1 mL RPMI and
CD28+ and CD28null, CD8+ and CD8- T cells were imme-
diately sorted on a FACSAria flow cytometer (BD).
1 × 103 sorted CD28+ and CD28 null T cells were
added to a Cytospin 4 cytocentrifuge (ThermoFisher Sci-
entific, Scorseby, Victoria, Australia) and centrifuged for
500 g for 5 min. Slides were air dried for 10 min and
cells fixed with 2.5% formalin in PBS for 10 min. Cytos-
pins were treated with 1% sodium dodecyl sulphate
(SDS, Sigma Aldrich, Castle Hill, NSW, Australia) in
PBS for 5 min, followed by 1 h incubation with a serum-
free protein blocker (Dako A/S, Glostrup, Denmark), over-
night incubation with 1/25 diluted GCR monoclonal anti-
body (Serotec, Abacus ALS, Brisbane, Australia), then
1 hour with AF549-conjugated goat polyclonal antibody to
mouse IgG1 (Invitrogen, Thornton, NSW, Australia), and
counterstained with DAPI (Sigma-Aldrich). Cells were
washed between incubation with 0.01 M Tris-buffered sa-
line pH 7.5, containing 0.05% Tween-20. Immunofluores-
cence was detected and imaged with a Zeiss fluorescence
microscope equipped with HBO 100 illuminating system,
AxioCam MRn digital camera and AxioVision 4.8.1 soft-
ware (Carl Zeiss GmbH, Goettingen, Germany).
Statistical analysis
Statistical analysis was performed using the Mann–
Whitney test. For T-cell subsets CD28null/CD8+/CD3+/
CD56-/CD45+/TNFα+/IFNγ+), a sample size of n = 10
allowed a power of 98–99.5% for analysis. Variance was
estimated from our previous studies [3-5,9-11]. Correla-
tions were performed using Spearman Rho correlation
tests. SPSS software was applied and differences between
groups of p < 0.05 considered significant.
Results
Increased CD28null CD8+ T and NKT-like cells in
COPD patients
There was a significant increase in CD28null CD8+ T
in patients with COPD compared with healthy controls
but no change in CD28null CD8- T cells (CD28nullCD8 +
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for COPD patients (controls) (mean ± sd)) consistent
with our previous findings for CD28null T cells [5].
There was a significant increase in CD28null CD8+
NKT-like cells in patients with COPD compared with
healthy controls but no change in CD28null CD8- NKT-
like cells (CD28nullCD8 +NKT-like: 38 ± 6.4 (23 ± 4.3);
CD28nullCD8-T: 8.3 ± 3.1 (7.4 ± 2.8) for COPD patients
(controls)).
Pgp1 expression by CD28+ and CD28null T, NKT-like cells
There were no significant differences in Pgp1 expression
by stimulated CD28+ or CD28 null CD8- or CD8+ CD3+
T or NKT-like cells from either COPD patients or con-
trols (data for COPD T cells shown in Figure 1) ( Data for
controls and NKT-like cells not shown).
GCR expression by CD28+ and CD28null T and NKT-like
cells
There was a significant decrease in the percentage of
CD28null/CD8- and CD28nullCD8+ T cells and NKT-
like cells expressing GCR in both COPD groups and
controls compared with their CD28+ T and NKT-like
cells (Data for T cell and NKT-like cell subsets from
COPD group shown in Figure 2a and b respectively)
(data for controls not shown). There was a significant
decrease in the percentage of CD8 + CD28null T cells
expressing GCR compared with CD8-CD28null T cells
(Figure 2a) and NKT-like cells (Figure 2b) from COPD


















Figure 1 The percentage of CD28+ and CD28null CD8+ (clear bars) an
presented as box plots. There was no significant change in the percentage
CD8-CD28+ T cells in patients with COPD (p > 0.05 for all).Correlation between GCR and IFNγ and TNFα production
in T and NKT-like cells
There was a significant correlation between GCR expres-
sion and the percentage of CD8 + CD28null T cells and
NKT-like cells producing IFNγ (Figure 3a) and TNFα
(Figure 3b) from both COPD groups and controls (data
for controls and NKT-like cells not shown).
Correlation between GCR and steroid binding in T and
NKT-like cells
Low GCR expression correlated with low Dex-Fluor bind-
ing for both COPD patients and control subjects (Figure 4)
and NKT-like cells (data not shown).
GCR expression of CD28+ and CD28null T cells by
Fluorescent Microscopy
Sorted CD28+ and CD28null T cells were stained for
GCR expression. There was significant positive stain-
ing with GCR in CD28+ T cells compared with CD28
null T cells using fluorescence microscopy (Figure 5).
GCR staining was mainly located in the CD28+ T cell
nucleus (Figure 5).
GCR expression in the cytoplasm and nucleus of CD28+
T cells compared with CD28 null T cells
To confirm nuclear staining of GCR in CD28+ T cells,
differential expression of GCR in the cytoplasm and nu-
cleus of CD28+ and CD28null T and NKT-like cells was
performed. There was a significant increase in GCR ex-
pression in the cytoplasm and nucleus of CD8 + CD28+             CD8-28null      CD8-28+
ns
d CD8- T cells expressing Pgp1 in patients with COPD. Data












































Figure 2 The percentage of CD28+ and CD28null CD8+ (clear bars) and CD8- NKT-like cells expressing GCR in patients with COPD.
a. The percentage of CD28+ and CD28null CD8+ (clear bars) and CD8- T cells expressing GCR in patients with COPD. Data presented as box plots. There
was a significant decrease in the percentage of CD28null/CD8- and CD28nullCD8+ T cells expressing GCR compared with CD28 + CD8- and CD28 + CD8+
T cells. There was a significant decrease in the percentage of CD8 + CD28null T cells expressing GCR compared with CD8-CD28null T cells. b. The percentage
of CD28+ and CD28null CD8+ (clear bars) and CD8- NKT-like cells expressing GCR in patients with COPD. Data presented as box plots. There was a significant
decrease in the percentage of CD28null/CD8- T and CD28nullCD8+ NKT-like cells expressing GCR compared with CD28+CD8- T and CD28+CD8+ NKT-like
cells. There was a significant decrease in the percentage of CD8+CD28null NKT-like cells expressing GCR compared with CD8-CD28null T cells.

































Figure 3 There was a significant negative correlation between GCR expression and the percentage of CD8 + CD28null T cells
producing IFNγ (a) and TNFα (b) from COPD patients.
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proportion of GCR expression in the cytoplasm/nucleus
of both subsets was similar. Representative flow cytome-
try plots showing expression of GCR in CD8 + CD28null
and CD8 + CD28+ T cells in the cytoplasm and nucleus
following stimulation are shown in Figure 6.
Correlation between GCR and FEV1
There was a significant negative correlation between FEV1
of COPD patients and the percentage of GCR negative

















Figure 4 There was a significant negative correlation between the pe
percentage of Dexamethasone Fluorescein positive cells from 10 COPDiscussion
Lymphocyte senescence and GC resistance have been
described in several other inflammatory conditions
such as cardiovascular disease [18], autoimmune dis-
ease [19], arthritis [20], IBD [21] associated with aging
[22] and aging with associated inflammation in COPD
[23]. This is the first study to show that lymphocyte
senescence in COPD is associated with a loss of GCR
from both T and NKT-like cells. Importantly, the loss of
GCR by increased numbers of senescent CD8 + CD28null






rcentage of GCR negative CD8 + CD28null T cells and the
D patients and 8 control subjects.
Figure 5 Representative immunofluorescence microphotos of GCR staining in sorted CD28null (left) and CD28+ T cells (middle).
Magenta is merged color of red (GCR) and blue (DAPI). Mean fluorescence intensity measured by ImageJ software was 160.5 ± 9.3 in CD28null
and 336.2 ± 25.0 in CD28+ cells (p < 0.001). Experiments were repeated 2 times, showing similar results.
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inflammatory CD8+ T cells in peripheral blood and
lungs [3] and an increase in cytotoxic NKT-like and NK
cells in the airways in COPD patients compared to
healthy and never-smokers [9]. Consistent with this we
identified increased CD8/CD28null cells in both current
and ex-smoker COPD groups [5]. Senescent CD28null
T and NKT-like cells have been shown to be more pro-
inflammatory and cytotoxic than their CD28 positive
counterparts [5,9], and exhibit a relative resistance to
corticosteroids [10]. The mechanism for this resistance
was at least partially explained by our findings of an in-
crease in the drug efflux pump Pgp1 in pro-inflammatory






Figure 6 Representative flow cytometry plots showing expression of
and nucleus following stimulation. There was a significant increase in GC
compared with CD8 + CD28null cells (p < 0.05 for all, from 5 experiments).did not differentiate Pgp1 expression on CD28+ and
CD28null T and NKT-like cells in this previous study.
We also hypothesized that steroid resistant senescent
lymphocytes may have decreased levels of GCR. There
have been reports of reduced GCR number in PBMC in
patients with steroid resistant asthma [24] and import-
antly, reduced GCRα protein expression in the periph-
eral lung of patients with COPD and smokers with
normal lung function [25]. However, there have been no
reports of decreased GCR expression in the peripheral
blood of patients with COPD, or in the various lymphocyte
subsets. Our current study shows there is a significant loss
of GCR expression in CD28null T and NKT-like subsets,






GCR in CD8 + CD28null and CD8 + CD28+ T cells in the cytoplasm




























Figure 7 There was a significant negative correlation between FEV1 % predicted and the percentage of GCR negative CD8 + CD28null
T cells in COPD patients.
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Importantly, these GCR deficient lymphocytes were
shown to be present in the systemic circulation of COPD
patients. Barnes et al. proposed a spillover of cells from
the lungs into the systemic circulation [2], which suggest
these GCR deficient cells may have originated in the lung.
There have been conflicting reports that either support or
dispute this concept. One report showed no difference in
GCR expression in lung follicular CD8 cells between
COPD patients and smokers [26] using immunofluores-
cence techniques. This study did not however differentiate
between GCR expression in CD28+ and CD28null subsets
of CD8 T cells. Another study of patients with interstitial
lung disease showed decreased expression of GCR mRNA
in lung tissue from steroid resistant compared with steroid
sensitive patients [27].
We then investigated the intracellular localization of
GCR in the various lymphocyte subsets and showed re-
duced cytoplasmic and nuclear GCR expression in
CD28null compared with CD28+ T and NKT-like cells.
Following stimulation there was a similar proportion of
GCR in the cytoplasm and nucleus of both CD28null
and CD28+ CD8+ T cells from both COPD patients and
control subjects, suggesting there is no defect in nu-
clear translocation of the GCR between these subsets.
Interestingly, our present study showed that a loss of
GCR expression by CD28null T and NKT-like cells was
also observed in healthy control subjects although at
decreased numbers compared with patients with COPD
ie., GCR expression was the same in CD28null T andNKT-like cells from both subject groups. One could
speculate that these cells may be the precursors to po-
tential inflammatory diseases. Our findings suggest that
the relative GC resistance of the CD28null inflamma-
tory lymphocytes need to be considered with any thera-
peutic approaches, and alternative therapies to GC may
be required to avoid susceptibility to inflammatory dis-
eases. To our knowledge, there have been no treatments
to date that have increased lymphocyte GCR expres-
sion, although there has been a report of successful
pitavastatin treatment of acute lung injury in septic
mice with associated increase in GCR in alveolar mac-
rophages [28] and in studies using selective GCR ago-
nists in the treatment of inflammatory bowel disease
[29]. Investigation of the possible effects of these thera-
peutics on GCR expression in CD28null CD8+ T cells
would be worthwhile. We have previously shown
CD137 is increased in CD28null T and NKT-like cells
in COPD [30]. In this previous study there was a sig-
nificant decrease in the percentage of CD28null T and
NKT-like cells producing IFNγ and TNFα in the pres-
ence of anti-CD137 blocking antibody compared with
CD28+ T and NKT-like counterparts suggesting these
pro-inflammatory cells may be targeted therapeutic-
ally. In conclusion, lymphocyte senescence in COPD is
associated with loss of GCR in CD28null T and NKT-
like cells. This loss is related to disease severity in
COPD, thus therapies aimed at increasing GCR expres-
sion in pro-inflammatory senescent lymphocytes
are warranted.
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